Matthew Langer Meyerson, Ph.D., M.D.
This page shows the publications co-authored by Matthew Meyerson and Kevin Buczkowski.
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov. 2018 01; 8(1):59-73.
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. . 2015 Oct; 14(10):2382-2389.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.